Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

Bayer205 enrolled

Overview

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

Study Type

OBSERVATIONAL

Enrollment

205

Conditions

Carcinoma, Renal Cell

Interventions

Sorafenib (Nexavar, BAY43-9006)DRUG

Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>/= 18 years * Diagnosis of renal cell carcinoma * Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2 * Patients in whom the oncologist has decide to start therapy with sorafenib. Exclusion Criteria: * Synonymous with contraindications to Nexavar.

Locations (1)

Unnamed facility

Many Locations, Poland

Outcomes

Primary Outcomes

Percentage of patients in whom the actual dose of sorafenib equaled the planned dose

Time frame: 12 months

Secondary Outcomes

Overall tolerability of treatment as measured by rate of adverse events

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.